ClinicalTrials.gg
Not yet recruitingNCT07428135HEARTUpdated Nov 9, 2026

Heart Failure Efficacy and Research Trial (HEART) Platform

An interventional study of Domain Intervention(s) and Control / Standard of Care Comparator in Heart Failure, sponsored by University of Alberta. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University of Alberta · Not applicable, Interventional, and Treatment

How we know

Updated Nov 5, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies in Heart Failure by University of Alberta — 11 open to participants now, 11 under way, none of them phase 3. Heart Failure · University of Alberta.

Planned enrollment
2nd of 25
1,000 · median 100
Started
2027
with 2 others
No phase
13 of 30
5 open now
Primary completion
2036-03
later than 10 of 10 live
Registered
26th of 30
by date

Among the 30 studies in Heart Failure by University of Alberta, this one is the 2nd largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2027, is one of 13 with no phase, reaches primary completion later than 10 of the 10 other live ones, and was the 26th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

11 of the 30 studies in Heart Failure by University of Alberta are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Heart Failure by University of Alberta, or all of them as a file.
02

Study summary

The Heart Failure Efficacy and Research Trial (HEART) Platform is a multicenter, randomized platform study designed to improve outcomes for patients with heart failure through the simultaneous and sequential evaluation of multiple interventions across the spectrum of heart failure.

Read the detailed description

The Heart Failure Efficacy and Research Trial (HEART) Platform is a multicenter, randomized platform clinical trial infrastructure designed to improve outcomes for adults with heart failure through the efficient and continuous evaluation of multiple interventions. The platform enables the simultaneous and sequential testing of therapies across the spectrum of heart failure, with the ability to add, modify, or close interventions ("domains") over time as evidence accumulates and new research questions emerge.

HEART uses a master protocol framework with Domain-Specific Appendices (DSAs) that provide intervention-specific eligibility criteria, procedures, safety monitoring, and outcomes, while using shared platform-wide processes for governance, operations, data collection, and participant protections. This modular documentation structure allows platform updates and domain evolution without requiring complete revisions to all platform components, supporting long-term sustainability and reduced regulatory burden.

Participants are enrolled into one of two mutually exclusive patient states at the time of randomization: (1) State 1: Worsening Heart Failure (WHF), which includes patients hospitalized or treated in the emergency department for acute heart failure requiring active management; and (2) State 2: Ambulatory Heart Failure, which includes stable outpatients with established heart failure receiving ongoing management and without recent heart failure hospitalization. Patient state determines eligibility for specific domains and supports state-specific analyses.

Each HEART domain operates as a semi-autonomous trial within the broader infrastructure, with domain-specific scientific leadership and funding, while benefiting from shared core trial procedures. Domains may be conducted as vanguard/feasibility studies, Phase II trials, or Phase III trials, depending on the maturity of evidence and research objectives, and interventions may advance ("graduate") to later-phase evaluations within the platform.

The default primary endpoint for Phase III trials within the platform is time to first event of death or cardiovascular hospitalization; however, specific primary outcomes are determined at the domain level to match the intervention and development phase.

The HEART Platform incorporates formal governance and safety oversight, including a Platform Steering Committee and independent Data Safety Monitoring Board (DSMB), with standardized adverse event definitions and reporting procedures. The platform is conducted in accordance with Good Clinical Practice, the Declaration of Helsinki, and applicable ethical and regulatory requirements, with ethics approval obtained for the master protocol and each individual domain.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are eligible for inclusion if they meet all of the following:
  • Age ≥18 years (or legal age of majority in participant's country of residence).
  • Diagnosis of heart failure, and eligible to be classified into one of the HEART platform states at the time of randomization:
  • State 1: Worsening Heart Failure (WHF): currently hospitalized for acute decompensated heart failure or emergency department patients requiring intravenous therapy for heart failure; OR
  • State 2: Ambulatory Heart Failure: stable outpatients with established heart failure diagnosis, receiving ongoing HF management and without HF hospitalization within the prior 30 days.
  • Able and willing to provide written (or consent via a legally authorized representative, where applicable).
  • Meets all applicable domain-specific eligibility criteria for at least one active HEART Platform domain at the time of screening/randomization.

Exclusion criteria

Exclusion Criteria (HEART Platform)

  • Participants will be excluded if any of the following apply:
  • Inability to provide (and no legally authorized representative available when applicable).
  • Not eligible for assignment to either HEART platform state (State 1 or State 2).
  • Presence of conditions or circumstances that, in the investigator's opinion, would make study participation unsafe or not feasible (e.g., inability to comply with study procedures or follow-up).
  • Does not meet the eligibility requirements for any active HEART Platform domain.
  • Any domain-specific exclusion criteria applicable to the intervention/domain(s) for which the participant would otherwise be eligible.
  • Additional inclusion and exclusion criteria apply for each individual HEART Platform domain and will be specified in the relevant domain protocol(s).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Active Domain Intervention(s)

    Participants will be randomized to receive one of the active intervention strategies being evaluated within eligible HEART Platform domains at the time of randomization. Eligible domains and interventions may change over time as domains are initiated, modified, or closed.

    Other: Domain Intervention(s)

  • Placebo comparator
    Control / Standard of Care Comparator

    Participants will be randomized to a concurrent control group within eligible HEART Platform domains. The control group may include placebo and/or standard-of-care management, as specified in each active domain protocol.

    Other: Control / Standard of Care Comparator

Interventions

  • OtherDomain Intervention(s)

    Participants randomized to the experimental arm will receive an intervention being evaluated within an eligible HEART Platform domain at the time of randomization. Domain interventions may change over time as domains are added, modified, or closed in accordance with the platform master protocol and domain-specific protocols.

  • OtherControl / Standard of Care Comparator

    Participants randomized to the comparator arm will receive concurrent control within eligible HEART Platform domains. Control may include placebo and/or standard-of-care management, depending on the domain-specific protocol.

06

What researchers measure

Primary outcomes

  1. Time to first occurrence of all-cause death or cardiovascular hospitalization

    Time from randomization to the first event of all-cause death or cardiovascular hospitalization. This represents the platform default primary endpoint for Phase III domain evaluations. Outcomes for each intervention are defined within each HEART Platform domain protocol. The outcome measures listed in this registration represent platform-level outcomes and default endpoints used across domains where applicable.

    Time frame: Up to 365 days (or as defined in domain-specific protocol)

Secondary outcomes

  1. All-cause mortality

    All-cause mortality after randomization.

    Time frame: Up to 365 days

  2. Cardiovascular hospitalization

    Occurrence of cardiovascular hospitalization after randomization.

    Time frame: Up to 365 days

  3. Heart failure hospitalization

    Occurrence of hospitalization due to worsening heart failure.

    Time frame: Up to 365 days

  4. All-cause hospitalization

    Occurrence of any hospitalization for any cause during the follow-up period of up to 365 days.

    Time frame: Up to 365 days

  5. Quality-adjusted days alive and out of the hospital

    Number of days alive and out of hospital following randomization, adjusted for health-related quality of life.

    Time frame: Up to 365 days

  6. Organ-support free days

    Number of days alive and free of organ support (e.g., mechanical ventilation, vasopressor therapy, or renal replacement therapy) within 30 days of enrollment.

    Time frame: Up to 30 days

  7. Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score

    KCCQ Overall Summary Score, a patient-reported measure of heart failure symptoms, physical and social function, and quality of life. Scores range from 0 to 100, with higher scores indicating better health status. Assessed at follow-up time points up to 365 days.

    Time frame: Up to 365 days

  8. EQ-5D-5L Health Utility Score

    Health-related quality of life measured using the EQ-5D-5L instrument. The EQ-5D-5L index score typically ranges from less than 0 (worse than death) to 1 (perfect health), with higher scores indicating better health status. Assessed at follow-up time points up to 365 days.

    Time frame: Up to 365 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Related links

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Mar 2036, 110 months later.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 110 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Feb 23, 2026
StartEst.
Jan 2027was Oct 2026
Primary completionEst.
Mar 2036
CompletionEst.
Mar 2037
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Jan 2027
Nov 5, 2026
Show all 2 updates
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: references
  2. Nov 5, 2026
    Start date Oct 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07428135
Collaborators
Canadian VIGOUR Centre
Responsible party
Sponsor
First posted
Feb 23, 2026
Start date
Jan 2027 (estimated)
Primary completion
Mar 2036 (estimated)
Completion
Mar 2037 (estimated)
Last update
Nov 9, 2026

Study contacts

Justin Ezekowitz, MD
Contact
jae2@ualberta.ca
780-492-0712
Justin Ezekowitz, MD
principal investigator · University of Alberta

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion